RemeGen Biosciences, Inc.
650 Gateway Blvd, Suite No. 110
South San Francisco
About RemeGen Biosciences, Inc.
RemeGen Biosciences is a biopharmaceutical company, focusing on the discovery and development of innovative biologics for the treatment of cancer and autoimmune diseases, based in South San Francisco, California, and Rockville, Maryland. By leveraging our deep insights into oncology and immunology, advanced protein engineering/design technologies, and extensive knowledge in clinical development, our vision is to uncover the novel therapeutic targets and develop the best-in-class and first-in-class biotherapeutics for the patients with significant unmet medical needs. RemeGen Bioscience is a wholly owned subsidiary of RemeGen Inc., a global pharmaceutic company specialized in autoimmune, oncology and ophthalmic diseases.
3 articles with RemeGen Biosciences, Inc.
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021
YANTAI, China , Dec. 14, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create clinical value, and meet the major unmet clinical needs of the world. Since 19
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment
RemeGen Co., Ltd. announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept for treating systemic lupus erythematosus and a novel antibody-drug conjugate, Disitamab Vedotin for treating locally advanced or metastatic gastric cancer, have been officially included in this year's National Reimbursement Drug List.
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
Seagen Inc., a world leader and pioneer in antibody-drug conjugate therapies, and RemeGen Co., Ltd., a leading innovative biopharmaceutical company in China, announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC.